MX2020010116A - Compuestos macrociclicos como inhibidores de quinasas del receptor de tropomiosina (trk). - Google Patents
Compuestos macrociclicos como inhibidores de quinasas del receptor de tropomiosina (trk).Info
- Publication number
- MX2020010116A MX2020010116A MX2020010116A MX2020010116A MX2020010116A MX 2020010116 A MX2020010116 A MX 2020010116A MX 2020010116 A MX2020010116 A MX 2020010116A MX 2020010116 A MX2020010116 A MX 2020010116A MX 2020010116 A MX2020010116 A MX 2020010116A
- Authority
- MX
- Mexico
- Prior art keywords
- macrocyclic compounds
- kinases inhibitors
- trk kinases
- trk
- inhibitors
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains four or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
- C07D487/16—Peri-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/22—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains four or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D498/16—Peri-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D498/20—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains four or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/05—Isotopically modified compounds, e.g. labelled
Abstract
Se proporcionan ciertos inhibidores de TRK, sus composiciones farmacéuticas, y métodos de uso de los mismos.
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201862648999P | 2018-03-28 | 2018-03-28 | |
US201862674755P | 2018-05-22 | 2018-05-22 | |
US201862684535P | 2018-06-13 | 2018-06-13 | |
US201962800496P | 2019-02-02 | 2019-02-02 | |
PCT/CN2019/079909 WO2019184955A1 (en) | 2018-03-28 | 2019-03-27 | Macrocyclic compounds as trk kinases inhibitors |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2020010116A true MX2020010116A (es) | 2020-11-06 |
Family
ID=68060871
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2020010116A MX2020010116A (es) | 2018-03-28 | 2019-03-27 | Compuestos macrociclicos como inhibidores de quinasas del receptor de tropomiosina (trk). |
Country Status (10)
Country | Link |
---|---|
US (1) | US11555042B2 (es) |
EP (1) | EP3774812A4 (es) |
JP (1) | JP2021519297A (es) |
KR (1) | KR20200141041A (es) |
CN (1) | CN111971287B (es) |
AU (1) | AU2019241260B2 (es) |
BR (1) | BR112020019399A2 (es) |
CA (1) | CA3093140A1 (es) |
MX (1) | MX2020010116A (es) |
WO (1) | WO2019184955A1 (es) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA3081790C (en) | 2017-11-10 | 2023-03-07 | Angex Pharmaceutical, Inc. | Macrocyclic compounds as trk kinase inhibitors and uses thereof |
US20220162218A1 (en) * | 2018-04-25 | 2022-05-26 | Primegene (Beijing) Co., Ltd. | Diaryl macrocyclic compound and pharmaceutical composition, and use thereof |
CN113773335A (zh) * | 2019-06-21 | 2021-12-10 | 成都海博为药业有限公司 | 一种作为蛋白质激酶抑制剂的化合物及其制备方法和用途 |
CN113754682B (zh) * | 2020-06-04 | 2023-01-06 | 赛诺哈勃药业(成都)有限公司 | 具有大环结构的化合物及其用途 |
WO2021259309A1 (zh) * | 2020-06-24 | 2021-12-30 | 广州市恒诺康医药科技有限公司 | Glp-1受体激动剂及其药物组合物和用途 |
CN111875620B (zh) * | 2020-09-28 | 2020-12-11 | 上海美迪西生物医药股份有限公司 | 吡唑并嘧啶类大环衍生物及其应用 |
CN113582994B (zh) * | 2021-09-28 | 2022-02-11 | 北京鑫开元医药科技有限公司 | 具有trk激酶抑制活性的化合物、制备方法、组合物及其用途 |
Family Cites Families (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PL2918588T3 (pl) | 2010-05-20 | 2017-10-31 | Array Biopharma Inc | Związki makrocykliczne jako inhibitory kinazy TRK |
US20160171596A1 (en) | 2013-07-26 | 2016-06-16 | Essilor International (Compagnie Generale D'optique | Self-service prescription eyewear kiosk |
CN104672250B (zh) * | 2013-11-29 | 2017-11-07 | 广东东阳光药业有限公司 | 取代的杂芳基化合物及其组合物和用途 |
DK3572416T3 (da) * | 2014-01-24 | 2022-12-12 | Turning Point Therapeutics Inc | Diaryl-makrocykler som modulatorer af proteinkinaser |
EP3145929B1 (en) * | 2014-05-23 | 2021-01-13 | F. Hoffmann-La Roche AG | 5-chloro-2-difluoromethoxyphenyl pyrazolopyrimidine compounds which are jak inhibitors |
WO2016089797A1 (en) * | 2014-12-05 | 2016-06-09 | Merck Sharp & Dohme Corp. | Novel tricyclic compounds as inhibitors of mutant idh enzymes |
WO2017004342A1 (en) * | 2015-07-02 | 2017-01-05 | Tp Therapeutics, Inc. | Chiral diaryl macrocycles as modulators of protein kinases |
DK3325488T3 (da) * | 2015-07-21 | 2020-09-14 | Turning Point Therapeutics Inc | Chiral diaryl-makrocyklus og anvendelse deraf til behandling af cancer |
CA2995997A1 (en) * | 2015-08-26 | 2017-03-02 | Blueprint Medicines Corporation | Compounds and compositions useful for treating disorders related to ntrk |
CN108697708A (zh) * | 2015-10-26 | 2018-10-23 | 洛克索肿瘤学股份有限公司 | Trk抑制剂抗性癌症中的点突变以及与此相关的方法 |
WO2017114351A1 (en) * | 2015-12-27 | 2017-07-06 | Chongqing Fochon Pharmaceutical Co., Ltd. | Certain protein kinase inhibitors |
CN109071512A (zh) * | 2016-02-03 | 2018-12-21 | 重庆复创医药研究有限公司 | 作为激酶抑制剂的含磷化合物 |
EP3490564A4 (en) | 2016-07-28 | 2020-02-26 | Turning Point Therapeutics, Inc. | MACRO CYCLE Kinase Inhibitors |
CN109516999B (zh) * | 2017-11-01 | 2021-08-17 | 郑州泰基鸿诺医药股份有限公司 | 用作蛋白质激酶调节剂的化合物及其应用 |
-
2019
- 2019-03-27 US US17/042,385 patent/US11555042B2/en active Active
- 2019-03-27 EP EP19778044.8A patent/EP3774812A4/en not_active Withdrawn
- 2019-03-27 AU AU2019241260A patent/AU2019241260B2/en active Active
- 2019-03-27 CN CN201980023296.XA patent/CN111971287B/zh active Active
- 2019-03-27 WO PCT/CN2019/079909 patent/WO2019184955A1/en unknown
- 2019-03-27 CA CA3093140A patent/CA3093140A1/en active Pending
- 2019-03-27 BR BR112020019399-2A patent/BR112020019399A2/pt not_active Application Discontinuation
- 2019-03-27 JP JP2020551805A patent/JP2021519297A/ja active Pending
- 2019-03-27 MX MX2020010116A patent/MX2020010116A/es unknown
- 2019-03-27 KR KR1020207028688A patent/KR20200141041A/ko not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
EP3774812A1 (en) | 2021-02-17 |
AU2019241260B2 (en) | 2022-06-16 |
KR20200141041A (ko) | 2020-12-17 |
WO2019184955A1 (en) | 2019-10-03 |
BR112020019399A2 (pt) | 2021-01-05 |
US11555042B2 (en) | 2023-01-17 |
CN111971287A (zh) | 2020-11-20 |
AU2019241260A1 (en) | 2020-10-01 |
EP3774812A4 (en) | 2021-12-15 |
CA3093140A1 (en) | 2019-10-03 |
RU2020133631A (ru) | 2022-05-04 |
CN111971287B (zh) | 2023-06-02 |
RU2020133631A3 (es) | 2022-05-04 |
JP2021519297A (ja) | 2021-08-10 |
US20210139506A1 (en) | 2021-05-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2020010116A (es) | Compuestos macrociclicos como inhibidores de quinasas del receptor de tropomiosina (trk). | |
ZA201807256B (en) | Inhibitors of activin receptor-like kinase | |
MX2019001125A (es) | Inhibidores de cinasa macrociclica. | |
MX2021014441A (es) | Inhibidores del dominio asociado mejorador de la transcripcion (tead) y usos de los mismos. | |
MX2019012431A (es) | Inhibidores del receptor de hidrocarburos de arilo (ahr) de indol y usos de los mismos. | |
MX2021014443A (es) | Inhibidores del dominio asociado mejorador de la transcripcion (tead) y usos de los mismos. | |
MX2020007797A (es) | Inhibidores de la cinasa 2 de control general no desrepresible (gcn2) y usos de los mismos. | |
PH12020500033A1 (en) | Macrocyclic compounds and uses thereof | |
MX2020007799A (es) | Inhibidores de cinasa no derrepresible de control de aminoacido general 2 (gcn2) y sus usos. | |
MX2022004304A (es) | Agentes inductores de apoptosis. | |
PH12015502041B1 (en) | Heteroaryl compounds and uses thereof | |
EP3706749A4 (en) | MACROCYCLIC COMPOUNDS AS TRK CINEMA INHIBITORS AND THEIR USES | |
PH12018500408A1 (en) | Bicyclic compounds as atx inhibitors | |
MX2016015565A (es) | Ciertos inhibidores de la proteina quinasa. | |
MX2018001890A (es) | Compuestos biciclicos como inhibidores de autotaxina (atx). | |
MX2018001430A (es) | Nuevos compuestos biciclicos como inhibidores duales de autotaxina (atx)/anhidrasa carbonica (ca). | |
AU2017228405A8 (en) | Small molecule IRE1-alpha inhibitors | |
PH12019501639A1 (en) | Jaki selective inhibitors | |
NZ725917A (en) | Novel polymerase-i inhibitors, uses and methods for making them | |
MX2021004245A (es) | Inhibidores del receptor de hidrocarburos de arilo (ahr) de indol y usos de los mismos. | |
MX2020001793A (es) | Inhibidores del receptor de hidrocarburos de arilo (ahr) y usos de los mismos. | |
MX2017013874A (es) | Imidazopirazinas y pirazolopirimidinas y su uso como moduladores del receptor de ampa. | |
MX2017013875A (es) | Ciertos inhibidores de la proteína quinasa. | |
MX2022014007A (es) | Compuestos como inhibidores de bcl-2. | |
PH12020550253A1 (en) | Bicyclic compounds for use as rip1 kinase inhibitors |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
GB | Transfer or rights |
Owner name: FOCHON BIOSCIENCES, LTD. |